Sign up to save your podcasts
Or
Share Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Host: Pasi Antero Jänne, MD, PhD
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
View all episodes
Host: Pasi Antero Jänne, MD, PhD
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.